The Effects of Curcuminoids on Aberrant Crypt Foci in the Human Colon

Overview

The purpose of this study is to determine the effectiveness of curcumin in reducing the number of aberrant crypt foci (ACF) in the colon.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2007

Detailed Description

Laboratory studies have indicated that this agent, which is derived from plants and found in foods we eat, has anti-inflammatory properties and prevents colon cancer in animal studies. ACFs are small abnormalities in the lining of the colon that with time may grow into colorectal adenomas (also called polyps, growths or small masses of tissue on the lining of the colon or rectum which have the potential to become cancerous) which can then grow into adenocarcinomas (cancer) in the colon or rectum.

Interventions

  • Drug: sulindac
    • Sulindac 150 mg po BID
  • Drug: curcumin
    • Curcumin 250 mg po BID

Clinical Trial Outcome Measures

Primary Measures

  • To evaluate the effects of curcumin or the NSAID sulindac on the number of ACF in the left colon and rectum of normal volunteers found to have them on an initial magnifying chromoendoscopic screening exam
    • Time Frame: 48 months

Secondary Measures

  • To determine the turnover (proliferation, apoptosis, and differentiation) of colorectal epithelial cells in the crypts in situ in response to each treatment
    • Time Frame: 48 months

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects must be eligible for colorectal cancer (CRC) screening/surveillance by current criteria. – Subjects must have at least 5 ACF on eligibility chromosigmoidoscopy examination. Exclusion Criteria:

Subjects must not have:

  • Alcohol consumption of greater than 2 glasses of wine or beer per day or illicit recreational drug use – Platelet or coagulation abnormalities, or personal history of a bleeding disorder, including individuals taking warfarin. – High risk for developing endocarditis (history of endocarditis or rheumatic fever, cardiac valve prostheses, or mitral valve prolapse that requires antibiotic prophylaxis). – Uncontrolled hypertension, diabetes, or chronic congestive heart failure. – Renal insufficiency defined as a serum creatinine > 2.5 mg/dl – History of colorectal surgery with removal of the distal 60 cm of colon or rectum. – History of other gastrointestinal mucosal epithelial diseases (such as Barrett's esophagus, chronic or recurrent peptic ulcer disease, celiac sprue or other disorders of nutrient absorption).

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Medicine and Dentistry of New Jersey
  • Provider of Information About this Clinical Study
    • C. S. Yang, PhD, The Cancer Institute of New Jersey
  • Overall Official(s)
    • Yang CS, MD, Principal Investigator, Rutgers, The State University of New Jersey

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.